Partnership in Depth and Width

CARsgen Therapeutics announced in May 2015 a clinical collaboration with Shanghai Jiaotong University affiliated Renji Hospital in proof of the safety and efficacy of CARsgen’s innovative and proprietary CAR-T therapy for a wide range of cancerous indications.
CARsgen Therapeutics and Shanghai Cancer Institute in September 2015 announced that both enter into a 5-year research and development agreement for novel autologous CAR-T cell therapies based on target validation and demonstration, CAR-T development and next generation CAR-T technologies.
CARsgen Therapeutics and Shanghai Chest Hospital step into collaboration of initiating a study of implementing CAR-T cell therapy for advanced squamous cell lung cancer.